Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides

Advanced Drug Delivery Reviews

Volumn 61, Issue 3, 2009, Pages 226-232

  Mutwiri, George ^a   van Drunen Littel van den Hurk, Sylvia ^a   Babiuk, Lorne A ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

CpG DNA; Delivery; Formulation; Oligodeoxynucleotides; Polyphosphazenes; Toll like receptors

Indexed keywords

CPG DNA; DELIVERY; FORMULATION; OLIGODEOXYNUCLEOTIDES; POLYPHOSPHAZENES; TOLL-LIKE RECEPTORS;

DNA; GENES; MAMMALS; NUCLEIC ACIDS;

IMMUNOLOGY;

AGATOLIMOD; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CPG 2007; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; EMULSIGEN; EOTAXIN; GARDIQUIMOD; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 5; POLYELECTROLYTE; POLYPHOSPHAZENE DERIVATIVE; PROSTAGLANDIN E2; PSEUDOMONAS VACCINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPOTENTIATION; INNATE IMMUNITY; INTERFERON PRODUCTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SPECIES DIFFERENCE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL VACCINES; CPG ISLANDS; DRUG COMPOUNDING; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, INNATE; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; POLYMERS; TOLL-LIKE RECEPTOR 9; VIRAL VACCINES;

EID: 61749098194     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.004     Document Type: Review

References (91)

1. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., and Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160 (1998) 870-876
2. McCluskie M.J., and Krieg A.M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr. Top. Microbiol. Immunol. 311 (2006) 155-178
3. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21 (2002) 127-137
4. Mutwiri G., Benjamin P., Soita H., and Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 26 (2008) 2680-2688
5. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., and O'Hagan D.T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 (2008) 552-561
6. Ioannou X.P., Gomis S.M., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. Safety and efficacy of CpG-containing oligodeoxynucleotides as immunological adjuvants in rabbits. Vaccine 21 (2003) 4368-4372
7. Ioannou X.P., Griebel P., Mena A., Gomis S.M., Godson D.L., Mutwiri G., Hecker R., Babiuk L.A., and Van Drunen Littel-Van Den Hurk S. Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev. 13 (2003) 157-167
8. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J. Virol. 76 (2002) 9002-9010
9. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., Laframboise C., Al Adhami M.J., Khaliq Y., Seguin I., and Cameron D.W. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 (2004) 3136-3143
10. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., and Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89 (1969) 449-463
11. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., and Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89 (1969) 435-448
12. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89 (1969) 405-421
13. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., and Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969) 422-434
14. Oumouna M., Mapletoft J.W., Karvonen B.C., Babiuk L.A., and van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J. Virol. 79 (2005) 2024-2032
15. Mapletoft J.W., Oumouna M., Townsend H.G., Gomis S., Babiuk L.A., and van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 353 (2006) 316-323
16. Nichani A.K., Kaushik R.S., Mena A., Popowych Y., Dent D., Townsend H.G., Mutwiri G., Hecker R., Babiuk L.A., and Griebel P.J. CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep. Cell. Immunol. 227 (2004) 24-37
17. Nichani A.K., Mena A., Kaushik R.S., Mutwiri G.K., Townsend H.G., Hecker R., Krieg A.M., Babiuk L.A., and Griebel P.J. Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. Oligonucleotides 16 (2006) 58-67
18. Nichani A.K., Mena A., Popowych Y., Dent D., Townsend H.G., Mutwiri G.K., Hecker R., Babiuk L.A., and Griebel P.J. In vivo immunostimulatory effects of CpG oligodeoxynucleotide in cattle and sheep. Vet. Immunol. Immunopathol. 98 (2004) 17-29
19. Nichani A.K., Dar M.A., Krieg A.M., Mirakhur K.K., Kaushik R.S., Griebel P.J., Manuja A., Townsend H.G., Babiuk L.A., and Mutwiri G.K. Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. Vet. Immunol. Immunopathol. 115 (2007) 357-368
20. Bowersock T.L., and Martin S. Vaccine delivery to animals. Adv. Drug. Deliv. Rev. 38 (1999) 167-194
21. Gallucci S., Lolkema M., and Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5 (1999) 1249-1255
22. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12 (1994) 991-1045
23. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., and Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23 (2005) 1588-1595
24. Goto N., and Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol. Immunol. 26 (1982) 1121-1132
25. Goto N., Kato H., Maeyama J., Shibano M., Saito T., Yamaguchi J., and Yoshihara S. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15 (1997) 1364-1371
26. Rimaniol A.C., Gras G., Verdier F., Capel F., Grigoriev V.B., Porcheray F., Sauzeat E., Fournier J.G., Clayette P., Siegrist C.A., and Dormont D. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 (2004) 3127-3135
27. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 69 (2001) 1151-1159
28. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., and Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205 (2008) 869-882
29. De Gregorio E., Tritto E., and Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38 (2008) 2068-2071
30. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126
31. Franchi L., and Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38 (2008) 2085-2089
32. McNeal M.M., Rae M.N., and Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17 (1999) 1573-1580
33. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., Andrianov A.K., and Roberts B.E. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16 (1998) 92-98
34. Wu J.Y., Wade W.F., and Taylor R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect. Immun. 69 (2001) 7695-7702
35. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., Andrianov A.K., and Babiuk L.A. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25 (2007) 1204-1213
36. Moldoveanu Z., Love-Homan L., Huang W.Q., and Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 (1998) 1216-1224
37. Teloni R., von Hunolstein C., Mariotti S., Donati S., Orefici G., and Nisini R. Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs. Indian J. Med. Res. 119 (2004) 126-130 Suppl
38. Zuercher A.W., Horn M.P., Wu H., Song Z., Bundgaard C.J., Johansen H.K., Hoiby N., Marcus P., and Lang A.B. Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine 24 (2006) 4333-4342
39. Abe N., Kodama S., Hirano T., Eto M., and Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope 116 (2006) 407-412
40. Hoft D.F., Eickhoff C.S., Giddings O.K., Vasconcelos J.R., and Rodrigues M.M. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic Trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J. Immunol. 179 (2007) 6889-6900
41. Zhang L., Tian X., and Zhou F. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo. Int. Immunopharmacol. 7 (2007) 1732-1740
42. McCluskie M.J., and Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161 (1998) 4463-4466
43. McCluskie M.J., Weeratna R.D., and Davis H.L. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 19 (2001) 2657-2660
44. Jiang W., Baker H.J., and Smith B.F. Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun. 71 (2003) 40-46
45. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., Hayashi T., Takabayashi K., Barenholz Y., and Kedar E. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20 (2002) 3342-3354
46. Tafaghodi M., Sajadi Tabassi S.A., and Jaafari M.R. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int. J. Pharm. 319 (2006) 37-43
47. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., and Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J. Virol. 77 (2003) 13156-13160
48. Tebbey P.W., Scheuer C.A., Peek J.A., Zhu D., LaPierre N.A., Green B.A., Phillips E.D., Ibraghimov A.R., Eldridge J.H., and Hancock G.E. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 18 (2000) 2723-2734
49. Walsh E.E. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 11 (1993) 1135-1138
50. Tebbey P.W., Unczur C.A., LaPierre N.A., and Hancock G.E. A novel and effective intranasal immunization strategy for respiratory syncytial virus. Viral Immunol. 12 (1999) 41-45
51. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75 (2001) 11079-11087
52. Matsuoka T., Okamoto Y., Matsuzaki Z., Endo S., Ito E., Tsutsumi H., Williamson R.A., Sakurai H., Burton D.R., and Saito I. Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes. Clin. Exp. Immunol. 130 (2002) 386-392
53. Stott E.J., Taylor G., Ball L.A., Anderson K., Young K.K., King A.M., and Wertz G.W. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 61 (1987) 3855-3861
54. Cano F., Plotnicky-Gilquin H., Nguyen T.N., Liljeqvist S., Samuelson P., Bonnefoy J., Stahl S., and Robert A. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18 (2000) 2743-2752
55. Falcone V., Mihm D., Neumann-Haefelin D., Costa C., Nguyen T., Pozzi G., and Ricci S. Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G. FEMS Immunol. Med. Microbiol. 48 (2006) 116-122
56. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., and van Drunen Littel-van den Hurk S. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J. Gen. Virol. 89 (2008) 250-260
57. Gomis S., Babiuk L., Allan B., Willson P., Waters E., Ambrose N., Hecker R., and Potter A. Protection of neonatal chicks against a lethal challenge of Escherichia coli using DNA containing cytosine-phosphodiester-guanine motifs. Avian Dis. 48 (2004) 813-822
58. Gomis S., Babiuk L., Godson D.L., Allan B., Thrush T., Townsend H., Willson P., Waters E., Hecker R., and Potter A. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect. Immun. 71 (2003) 857-863
59. He H., Genovese K.J., Swaggerty C.L., Nisbet D.J., and Kogut M.H. In vivo priming heterophil innate immune functions and increasing resistance to Salmonella enteritidis infection in neonatal chickens by immune stimulatory CpG oligodeoxynucleotides. Vet. Immunol. Immunopathol. 117 (2007) 275-283
60. He H., Lowry V.K., Swaggerty C.L., Ferro P.J., and Kogut M.H. In vitro activation of chicken leukocytes and in vivo protection against Salmonella enteritidis organ invasion and peritoneal S. enteritidis infection-induced mortality in neonatal chickens by immunostimulatory CpG oligodeoxynucleotide. FEMS Immunol. Med. Microbiol. 43 (2005) 81-89
61. A. Taghavi, B. Allan, G. Mutwiri, M. Foldvari, A. Van Kessel, P. Willson, L. Babiuk, A. Potter, S. Gomis, Enhancement of immunoprotective effect of CpG ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens, Current Drug Delivery (in press).
62. Alcon V.L., Foldvari M., Snider M., Willson P., Gomis S., Hecker R., Babiuk L.A., and Baca-Estrada M.E. Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix). Vaccine 21 (2003) 1811-1814
63. Andrianov A.K., Marin A., and Roberts B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 6 (2005) 1375-1379
64. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2879-2883
65. Artavanis-Tsakonas K., Tongren J.E., and Riley E.M. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin. Exp. Immunol. 133 (2003) 145-152
66. Liew F.Y., Xu D., Brint E.K., and O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5 (2005) 446-458
67. Jarnicki A.G., Conroy H., Brereton C., Donnelly G., Toomey D., Walsh K., Sweeney C., Leavy O., Fletcher J., Lavelle E.C., Dunne P., and Mills K.H. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180 (2008) 3797-3806
68. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
69. Yi A.K., Yoon J.G., Yeo S.J., Hong S.C., English B.K., and Krieg A.M. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J. Immunol. 168 (2002) 4711-4720
70. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147 (1991) 3815-3822
71. Fiorentino D.F., Zlotnik A., Vieira P., Mosmann T.R., Howard M., Moore K.W., and O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146 (1991) 3444-3451
72. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22 (2004) 929-979
73. Trinchieri G. Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection. J. Exp. Med. 194 (2001) F53-57
74. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., and Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
75. Mills K.H. Regulatory T cells: friend or foe in immunity to infection?. Nat. Rev. Immunol. 4 (2004) 841-855
76. Mills K.H., and McGuirk P. Antigen-specific regulatory T cells-their induction and role in infection. Semin. Immunol. 16 (2004) 107-117
77. Brummel R., and Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J. Immunol. 174 (2005) 2429-2434
78. Lenert P., Brummel R., Field E.H., and Ashman R.F. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25 (2005) 29-40
79. Duramad O., Fearon K.L., Chan J.H., Kanzler H., Marshall J.D., Coffman R.L., and Barrat F.J. IL-10 regulates plasmacytoid dendritic cell response to CpG containing immunostimulatory sequences. Blood 102 13 (2003) 4487-4492
80. Hisaeda H., Maekawa Y., Iwakawa D., Okada H., Himeno K., Kishihara K., Tsukumo S., and Yasutomo K. Escape of malaria parasites from host immunity requires CD4+ CD25+ regulatory T cells. Nat. Med. 10 (2004) 29-30
81. Theiner G., Rossner S., Dalpke A., Bode K., Berger T., Gessner A., and Lutz M.B. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol. Immunol. 45 (2008) 244-252
82. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6 (2005) 769-776
83. Berghofer B., Haley G., Frommer T., Bein G., and Hackstein H. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production. J. Immunol. 178 (2007) 4072-4079
84. Marshall J.D., Heeke D.S., Gesner M.L., Livingston B., and Van Nest G. Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J. Leukoc. Biol. 82 (2007) 497-508
85. Bafica A., Santiago H.C., Goldszmid R., Ropert C., Gazzinelli R.T., and Sher A. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J. Immunol. 177 (2006) 3515-3519
86. Bafica A., Scanga C.A., Feng C.G., Leifer C., Cheever A., and Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J. Exp. Med. 202 (2005) 1715-1724
87. Hokey D.A., Larregina A.T., Erdos G., Watkins S.C., and Falo Jr. L.D. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 65 (2005) 10059-10067
88. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., and Williams B.R. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64 (2004) 5850-5860
89. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., Schmitt E., Schild H., and Radsak M.P. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108 (2006) 544-550
90. Bagchi A., Herrup E.A., Warren H.S., Trigilio J., Shin H.S., Valentine C., and Hellman J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178 (2007) 1164-1171
91. Tada H., Aiba S., Shibata K., Ohteki T., and Takada H. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect. Immun. 73 (2005) 7967-7976